Map Pharmaceuticals Overview

  • Founded
  • 2003
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 196
Employees
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $958M
Latest Deal Amount

Map Pharmaceuticals General Information

Description

Developer of novel inhalation therapies for respiratory and systemic diseases. The company develops innovative drug that focuses on providing better treatments for patients with neurological diseases.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Primary Office
  • 2400 Bayshore Parkway
  • Suite 200
  • Mountain View, CA 94043
  • United States
+1 (650) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Map Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Merger/Acquisition 23-Jan-2013 $958M 00000 00000 Completed Generating Revenue
8. PIPE 28-Jan-2010 0000 00000 Completed Generating Revenue
7. Debt - General 07-May-2008 0000 00000 Completed Generating Revenue
6. IPO 05-Oct-2007 0000 00000 00000 Completed Clinical Trials - Phase 3
5. Later Stage VC (Series D) 01-Mar-2007 000.00 00000 00000 Completed Generating Revenue
4. Debt - General 27-Dec-2006 000.00 Completed Clinical Trials - Phase 3
3. Later Stage VC (Series C) 01-Jan-2006 000.00 000.00 000.00 Completed Generating Revenue
2. Early Stage VC (Series B) 01-Aug-2004 $30M $31.5M 000.00 Completed Generating Revenue
1. Early Stage VC (Series A) 01-Mar-2004 $1.5M $1.5M 00.000 Completed Product Development
To view Map Pharmaceuticals’s complete valuation and funding history, request access »

Map Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D 0,000,000 00.000000 00 00.0 00.0 00 00.0 00.000
Series C 000,000 00.000000 00 00.0 00.0 00 00.0 0.000
Series B 8,282,223 $0.010000 8% $3.62 $3.62 1x $3.62 44.91%
Series A 1,080,000 $0.010000 8% $1.39 $1.39 1x $1.39 5.86%
To view Map Pharmaceuticals’s complete cap table history, request access »

Map Pharmaceuticals Executive Team (11)

Name Title Board Seat Contact Info
Anastasios Gianakakos Senior Vice President & Chief Business Officer
Marco Rosa Vice President, Human Resources
Thomas McCracken JD Vice President, Intellectual Property
Christopher Chai Chief Financial Officer & Senior Vice President
Thomas Armer Ph.D Founder & Chief Scientific Officer
You’re viewing 5 of 11 executive team members. Get the full list »

Map Pharmaceuticals Board Members (8)

Name Representing Role Since
Bernard Kelley Self Board Member 000 0000
Geraldine Henwood Self Board Member 000 0000
H. Ward Wolff Self Board Member 000 0000
Scott Ward Self Chairman 000 0000
W. James O'Shea Self Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Map Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Map Pharmaceuticals Former Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Aisling Capital Venture Capital Minority 000 0000 000000 0
Azimuth Opportunity Investment Bank Minority 000 0000 000000 0
Bay City Capital Venture Capital Minority 000 0000 000000 0
Brookside Capital Venture Capital Minority 000 0000 000000 0
Pequot Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »